Hypothesis

Chronic lipid peroxidation of mitochondrial complex I subunit NDUFS1 (generating HNE adducts) does not merely cause energetic failure; it re‑programs the senescent secretory phenotype to enforce a tissue‑wide growth arrest that limits proliferation of neighboring damaged cells. In this view, senescent cells are not passive casualties but active “checkpoint enforcers” whose SASP composition is shaped by specific oxidative mitochondrial signals.

Mechanistic Model

1. Oxidative trigger – Age‑related ROS produce HNE that covalently modifies lysine residues on NDUFS1, decreasing Complex I activity without lowering protein levels {1}.
2. Metabolic signaling – The resulting NADH/NAD+ imbalance stabilizes HIF‑1α under normoxic conditions, a shift previously linked to altered SASP in senescence {2},
3. SASP re‑programming – HIF‑1α drives transcription of a distinct SASP subset enriched in TGF‑β, IL‑10, and CXCL14, cytokines known to induce cell‑cycle arrest and attract regulatory immune cells.
4. Paracrine enforcement – Neighboring epithelial or stromal cells receiving these signals exhibit sustained p21^CIP1^ activation and reduced Ki‑67 indexing, effectively creating a growth‑checkpoint zone.
5. Immune modulation – HNE‑modified peptides presented on MHC‑I recruit CD8^+ T cells that secrete IFN‑γ, reinforcing the arrest loop without triggering overt inflammation. Thus, lipid peroxidation‑derived mitochondrial damage converts senescence from a passive decline into an active tissue‑protective checkpoint.

Testable Predictions

• Prediction 1: Cells with induced HNE‑NDUFS1 adducts (via targeted lipoperoxidation or HNE‑treated lysates) will show elevated HIF‑1α nuclear accumulation and a SASP profile skewed toward TGF‑β/IL‑10 relative to controls.
• Prediction 2: Conditioned medium from HNE‑NDUFS1‑modified senescent cells will reduce proliferation and increase p21 expression in co‑cultured primary fibroblasts or organoids, an effect neutralized by TGF‑β or IL‑10 blocking antibodies.
• Prediction 3: In vivo, genetic knock‑in of a HNE‑resistant NDUFS1 mutant (lysine→arginine) in mice will diminish the checkpoint SASP, leading to hyperproliferation of adjacent epithelium after carcinogen challenge and increased tumor incidence.
• Prediction 4: Depletion of senescent cells using a senolytic in wild‑type mice will transiently elevate neighboring cell proliferation markers, which can be rescued by exogenous TGF‑β administration.

Experimental Approach

• In vitro: Treat human IMR‑90 fibroblasts with sub‑lethal linoleic acid peroxidation products to generate HNE‑NDUFS1 adducts (validated by anti‑HNE Western blot and mass spectrometry). Measure HIF‑1α stabilization (immunofluorescence), SASP cytokine arrays, and perform transwell proliferation assays with reporter epithelial cells.
• In vivo: Generate a knock‑in mouse line expressing NDUFS1‑K→R at major HNE sites. Subject young and aged mice to low‑dose DMBA to induce epidermal damage. Assess senescent cell burden (p16^INK4a^ staining), SASP composition (ELISA of skin extracts), neighbor proliferation (Ki‑67), and tumor formation over 6 months.
• Intervention: Apply navitoclax senolytic to wild‑type mice post‑DMBA; monitor proliferation spikes and test rescue with topical TGF‑β.

Potential Implications

If validated, this hypothesis reframes senescence as a lipid‑damage‑sensing safeguard that restrains neoplastic expansion. It suggests that indiscriminate senolytic use may breach a natural tumor‑suppressive barrier, necessitating strategies that either preserve the checkpoint SASP or selectively remove only senescent cells lacking the HNE‑NDUFS1‑HIF‑1α signature. Moreover, it opens therapeutic avenues to boost the checkpoint axis (e.g., HIF‑1α stabilizers or TGF‑β mimetics) in high‑risk tissues to prevent cancer initiation.